Open an account

Apnimed

APMD · NASDAQ

$18.51+$1.92 (+11.54%)TodayMarket closed ·
Prev close $16.60

About APMD

Apnimed Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2026-07-31. Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The firm's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.

Employees
0
Headquarters
Cambridge, Massachusetts
Listed
Jul 31, 2026
Sector
Health Care
Industry
Pharmaceuticals
Website
apnimed.com

APMD key statistics

Market cap
770.59M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
536.77K
Volume
311.12K
Open price
$16.64
High today
$18.80
Low today
$16.43
52 Week high
$35.29
52 Week low
$16.12

Apnimed (APMD) at a glance

As of Oct 20, 2026, Apnimed (APMD) shares are priced at $18.51, giving the company a market cap of 770.59M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $16.43 and $18.80. The current price is 12.7% above the day's low and 1.5% below its high.

Volume so far is 311.12K shares, below the average of 536.77K shares a day.

Over the past year Apnimed has ranged from $16.12 to $35.29, and now sits 12% of the way up that range.

The average analyst price target is $51.34, 177.4% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $51.34
Low
$41.41
Now
$18.51
High
$63.00

APMD news

  • Press releasePRNewswire

    Apnimed Announces Pricing of Upsized Initial Public Offering

Similar companies

Companies in the same industry as Apnimed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.